🚀 VC round data is live in beta, check it out!
Cosmecca Korea Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cosmecca Korea and similar public comparables like Tempo Scan Pacific, Alkaloid, Sunmax Biotechnology, Betterware de Mexico and more.
Cosmecca Korea Overview
About Cosmecca Korea
Cosmecca Korea Co Ltd is engaged in research, development, and production of cosmetics. It offers various products including skincare, makeup products, and functional products. The skincare products consist of Cream, Essence, Cleansers, Korean herbal products, Exfoliators, and mask sheets. Its functional products comprise of skincare products with specific functions such as UV blocking, brightening, and wrinkle care. The Makeup products range comprise of BB & CC cream, Skin cover balms, Makeup base, Foundation, Concealer, Lipstick, Mascara, and Powders.
Founded
1999
HQ
Employees
450
Website
Sectors
Financials (LTM)
EV
$675M
Cosmecca Korea Financials
Cosmecca Korea reported last 12-month revenue of $461M and EBITDA of $74M.
In the same LTM period, Cosmecca Korea generated $114M in gross profit, $74M in EBITDA, and $38M in net income.
Revenue (LTM)
Cosmecca Korea P&L
In the most recent fiscal year, Cosmecca Korea reported revenue of $443M and EBITDA of $70M.
Cosmecca Korea expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $461M | XXX | $443M | XXX | XXX | XXX |
| Gross Profit | $114M | XXX | $108M | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | $74M | XXX | $70M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $38M | XXX | $34M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $66M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cosmecca Korea Stock Performance
Cosmecca Korea has current market cap of $614M, and enterprise value of $675M.
Market Cap Evolution
Cosmecca Korea's stock price is $57.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $675M | $614M | 0.0% | XXX | XXX | XXX | $3.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCosmecca Korea Valuation Multiples
Cosmecca Korea trades at 1.5x EV/Revenue multiple, and 9.2x EV/EBITDA.
EV / Revenue (LTM)
Cosmecca Korea Financial Valuation Multiples
As of April 20, 2026, Cosmecca Korea has market cap of $614M and EV of $675M.
Equity research analysts estimate Cosmecca Korea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cosmecca Korea has a P/E ratio of 16.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $614M | XXX | $614M | XXX | XXX | XXX |
| EV (current) | $675M | XXX | $675M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 9.2x | XXX | 9.7x | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | 11.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | 6.3x | XXX | XXX | XXX |
| P/E | 16.3x | XXX | 18.1x | XXX | XXX | XXX |
| EV/FCF | 48.0x | XXX | 297.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cosmecca Korea Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cosmecca Korea Margins & Growth Rates
Cosmecca Korea's revenue in the last 12 month grew by 13%.
Cosmecca Korea's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.1M for the same period.
Cosmecca Korea's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cosmecca Korea's rule of X is 54% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cosmecca Korea Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 11% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cosmecca Korea Public Comps
See public comps and valuation multiples for other Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cosmecca Korea | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempo Scan Pacific | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkaloid | XXX | XXX | XXX | XXX | XXX | XXX |
| Sunmax Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Betterware de Mexico | XXX | XXX | XXX | XXX | XXX | XXX |
| PZ Cussons | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cosmecca Korea M&A Activity
Cosmecca Korea acquired XXX companies to date.
Last acquisition by Cosmecca Korea was on XXXXXXXX, XXXXX. Cosmecca Korea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cosmecca Korea
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCosmecca Korea Investment Activity
Cosmecca Korea invested in XXX companies to date.
Cosmecca Korea made its latest investment on XXXXXXXX, XXXXX. Cosmecca Korea invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cosmecca Korea
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cosmecca Korea
| When was Cosmecca Korea founded? | Cosmecca Korea was founded in 1999. |
| Where is Cosmecca Korea headquartered? | Cosmecca Korea is headquartered in South Korea. |
| How many employees does Cosmecca Korea have? | As of today, Cosmecca Korea has over 450 employees. |
| Who is the CEO of Cosmecca Korea? | Cosmecca Korea's CEO is Lim-Rae Jo. |
| Is Cosmecca Korea publicly listed? | Yes, Cosmecca Korea is a public company listed on Korea Exchange. |
| What is the stock symbol of Cosmecca Korea? | Cosmecca Korea trades under 241710 ticker. |
| When did Cosmecca Korea go public? | Cosmecca Korea went public in 2016. |
| Who are competitors of Cosmecca Korea? | Cosmecca Korea main competitors are Tempo Scan Pacific, Alkaloid, Sunmax Biotechnology, Betterware de Mexico. |
| What is the current market cap of Cosmecca Korea? | Cosmecca Korea's current market cap is $614M. |
| What is the current revenue of Cosmecca Korea? | Cosmecca Korea's last 12 months revenue is $461M. |
| What is the current revenue growth of Cosmecca Korea? | Cosmecca Korea revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Cosmecca Korea? | Current revenue multiple of Cosmecca Korea is 1.5x. |
| Is Cosmecca Korea profitable? | Yes, Cosmecca Korea is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cosmecca Korea? | Cosmecca Korea's last 12 months EBITDA is $74M. |
| What is Cosmecca Korea's EBITDA margin? | Cosmecca Korea's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Cosmecca Korea? | Current EBITDA multiple of Cosmecca Korea is 9.2x. |
| What is the current FCF of Cosmecca Korea? | Cosmecca Korea's last 12 months FCF is $14M. |
| What is Cosmecca Korea's FCF margin? | Cosmecca Korea's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Cosmecca Korea? | Current FCF multiple of Cosmecca Korea is 48.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.